Nephrocalcinosis at Baseline Did Not Increase the Risk of Nephrocalci-nosis Progression After Long-Term Burosumab Treatment in Adults and Children with X-Linked Hypophosphatemia (XLH). Read more about Nephrocalcinosis at Baseline Did Not Increase the Risk of Nephrocalci-nosis Progression After Long-Term Burosumab Treatment in Adults and Children with X-Linked Hypophosphatemia (XLH).